S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML

Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL trial (NCT03106779) evaluating asciminib (Scemblix) vs bosutinib (Bosulif) and data with ponatinib (Iclusig) from a post hoc analysis of the phase 2 OPTIC trial (NCT02467270).